Companies ›Healthcare ›ATNM

ATNM — NYSE Pharmaceuticals & Medical Research

Actinium Pharmaceuticals, Inc.

$0,81

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

25,3M USD

P/E

—

EV / Rev

-65,5x

Div yield

—

Op margin

-40 274,4 %

ROE

-1 470,8 %

Net margin

-37 652,2 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,97

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Actinium Pharmaceuticals, Inc. operates in the pharmaceuticals sector, focusing on radiopharmaceuticals with a distribution network serving approximately 50 leading hospitals.

Business. Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY3 analysts

2 buy1 hold0 sell

Avg 12m price target3,67

Analyst recommendations

3 analysts · consensus Buy

Buy2

Hold1

Sell0

12-month price target

3,67

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

3 analysts · indicative

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-1 470,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ATNM.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ATNM. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

Actinium Pharmaceuticals maintains a strong liquidity position with a current ratio of 5.89 and $42.1 million in cash and equivalents against total liabilities of $43.1 million. The balance sheet shows zero debt-to-equity, indicating no interest-bearing debt obligations. However, the company reports negative operating income of -$5.9 million and negative free cash flow of -$5.9 million for Q1 2026, reflecting ongoing pre-commercial or early-commercial burn rates typical of specialized pharmaceutical developers.

Profitability metrics are negative, with a return on equity of -14.7% and return on assets of -0.75%, consistent with a company investing in clinical development and supply chain infrastructure rather than generating net income. The price-to-book ratio stands at 15.73, suggesting the market values intangible assets such as intellectual property and regulatory approvals significantly above tangible book value. EV/EBITDA is near zero at 0.16, reflecting the lack of positive EBITDA.

Revenue concentration is not explicitly detailed in segment breakdowns, but the company highlights a distribution network reaching approximately 50 leading hospitals and multiple redundant isotope supply agreements. This infrastructure suggests a focus on reliable supply chain coverage across major metropolitan areas to serve patient demand at clinical scale.

Growth trajectory data is limited to the Q1 2026 snapshot, which shows net income of -$5.5 million. The company’s financial model relies on scaling distribution and potentially collaborative arrangements, as indicated by accounting guidance references for collaboration agreements. Without historical revenue trends, long-term growth visibility remains dependent on regulatory approvals and commercial adoption of its radiopharmaceutical products.

Risk factors include medium dilution risk, as source documents mention dilution or offering risk. Liquidity risk is assessed as low due to strong cash reserves. Key operational risks involve regulatory compliance with FDA and EMA guidelines for radiopharmaceuticals, including dosimetry assessments and manufacturing controls.

Recent events highlight a critical listing risk: the stock price fell below $1.00 to $0.97 on July 8, 2026, triggering a US continued-listing minimum-bid threshold alert. This price level has persisted for six consecutive days, posing a potential delisting threat if not resolved. Analyst sentiment remains cautiously optimistic, with a mean price target of $3.67 and a median of $4.00, though no strong-buy recommendations exist.

Key takeaways

Strong liquidity with $42.1M cash and 5.89 current ratio offsets negative cash flow of -$5.9M.
Zero debt-to-equity provides financial flexibility but negative ROE (-14.7%) indicates ongoing losses.
Medium dilution risk flagged in source documents suggests potential equity offerings to fund operations.
Stock price below $1.00 ($0.97) triggers NYSE continued-listing risk, requiring immediate attention.
Analyst price targets ($3.67 mean) imply significant upside from current levels, contingent on regulatory and commercial progress.
Distribution network to 50 hospitals supports supply chain resilience for radiopharmaceutical products.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Operating income -$5.9M.

Revenue—

Operating income-$5.9M

Net income-$5.5M

Free cash flow-$5.9M

EPS—

Operating cash flow-$5.9M

Financials

Income statement

Revenue—

Gross profit—

Operating income-$5.9M

Net income-$5.5M

Balance sheet

Total assets$45.4M

Total liabilities$43.1M

Total equity$2.3M

Cash & equivalents$42.1M

Long-term debt—

Cash flow

Operating cash flow-$5.9M

CapEx$2.0k

Free cash flow-$5.9M

SBC$11.0k

Highlights

▍Operating income -$5.9M

Valuation FY

Market price

$0,81

Market cap

$36.2M

Enterprise valueⓘ

-$5.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

-65.5x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

15.7x

P / Tangible bookⓘ

15.7x

Tangible book

$2.3M

Net cashⓘ

$42.1M

Current ratioⓘ

5.9

Debt / equityⓘ

—

ROAⓘ

-74.6%

ROEⓘ

-14.7%

Cash conversionⓘ

73.0%

CapEx / revenueⓘ

1.2%

SBC / revenueⓘ

102.1%

Dilution ratioⓘ

-0.4%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs ATNM · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

+1 511,2 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

+1 423,0 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

+1 310,6 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

+1 475,9 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

+1 489,7 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

+1 413,3 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,91

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,85
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-33,1M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy0

Buy2

Hold1

Sell0

Strong sell0

12-month price target$3,67 · Median $4,00

Low $2,00High $5,00

Operating income · consensus-33,1M USD

EPS surprise

−28,7 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,00

Mean$3,67

Median$4,00

High$5,00

Spot$0,81

+351.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-40 274,4 %Bottom quartile

Net Margin-37 652,2 %Bottom quartile

ROE-1 470,8 %Bottom quartile

Capex / Rev115,6 %Best in class

D/E0,00Above median

Cash Conv0,73Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Ev To Revenue
enterprise_value / revenue
Market Cap
market_price * shares_outstanding_diluted
Return On Assets
net_income / total_assets
Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Enterprise Value
market_cap - net_cash

Source documents

Actinium Pharmaceuticals, Inc. company facts · 2026-07-12
Actinium Pharmaceuticals, Inc. 10-Q 2026-05-08 · 2026-07-12
Actinium Pharmaceuticals, Inc. 10-K 2026-03-30 · 2026-07-12
Actinium Pharmaceuticals, Inc. 10-Q 2025-11-14 · 2026-07-12
Actinium Pharmaceuticals, Inc. 10-Q 2025-08-08 · 2026-07-12
ha_price_listing fired on ATNM · 2026-07-12
Actinium Pharmaceuticals Inc Market data — analyst estimates · 2026-07-12
Actinium Pharmaceuticals Inc Market data — ESG · 2026-07-12

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$14M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$2M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Mixed / flat0 buys · 0 sellsnet $01 insiders · last 365d

SETH SANDESHDirector, Chief Executive Officer · Common StockOther 120 900 @ $1,71$207K · 2025-08-18

Short positioning

820.1Kshares short-12.5% vs prior

8.63days to cover

53.0%short of daily vol

5.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ATNMCanonical

NYSE · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Evidence & claims

From filings & derived data

Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.2%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.7%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 14.2%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 11.4%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2023-12-31): 11.1%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
Net margin (FY 2025-12-31): -37,652.2%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
Return on equity (FY 2025-12-31): -432.6%Derived (calculated)
Return on assets (FY 2025-12-31): -65.5%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -76.1%Derived (calculated)
Current ratio (FY 2025-12-31): 6.20xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 14.2%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 5.61xDerived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -29.7%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 845.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 13.9%Derived (calculated)
EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
Revenue (annual): USD 90KSEC XBRL filing
Shares outstanding (annual): 31.2MSEC XBRL filing
Current assets (annual): USD 49.38MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
R&D expense (annual): USD 21.12MSEC XBRL filing
Operating income (annual): USD -36.25MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-08 21:47 UTCEVENTHa Price Listing ATNM price below 1 ($0.97) — US continued-listing minimum-bid threshold

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-18FILINGCURRENT REPORT →

2026-05-29FILINGCURRENT REPORT →

2026-05-08FILINGQUARTERLY REPORT →

2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -5.5M

2026-03-30FILINGANNUAL REPORT →

2026-02-13FILINGCURRENT REPORT →

2025-12-31EARNINGSQuarterly results — Q3 2025

2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 0.1M · Net USD -33.9M

2025-11-26FILINGCURRENT REPORT →

2025-11-14FILINGQUARTERLY REPORT →

2025-11-05FILINGPROXY STATEMENT →

2025-09-30EARNINGSQuarterly results — Q2 2025 Revenue USD 0.1M · Net USD -27.9M

2025-08-18 00:00 UTCINSIDER1 insider transaction — 2025-08 · net sell $207k

2025-08-18INSIDERSETH SANDESH transacted 120.9k sh — Director, Chief Executive Officer ~$207k

2025-08-08FILINGQUARTERLY REPORT →

2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -22.8M

2025-05-09FILINGQUARTERLY REPORT →

2025-05-09FILINGCURRENT REPORT →

2025-03-31 00:00 UTCINSIDER38 insider transactions — 2025-03 38 derivative

2025-03-31FILINGANNUAL REPORT →

2024-12-31EARNINGSAnnual results — FY 2024 Net USD -38.2M

2024-11-01 00:00 UTCINSIDER1 insider transaction — 2024-11 1 derivative

2023-12-31EARNINGSAnnual results — FY 2023 Revenue USD 0.1M · Net USD -48.8M

2023-12-28 00:00 UTCINSIDER6 insider transactions — 2023-12 6 derivative

2022-08-17 00:00 UTCINSIDER1 insider transaction — 2022-08

2022-07-01 00:00 UTCINSIDER6 insider transactions — 2022-07 6 derivative

2021-09-01 00:00 UTCINSIDER2 insider transactions — 2021-09 2 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread